



CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO: 4071WB000781 AGE/SEX :28 Years Female MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

DRAWN

RECEIVED: 04/02/2023 09:12:37

REPORTED :05/02/2023 13:22:50

Test Report Status Results Biological Reference Interval Units **Preliminary**

ABHA NO

MEDIWHEEL HEALTH CHECKUP BELOW 40(F)TMT

TREADMILL TEST

TREADMILL TEST REPORTED

OPTHAL

REPORTED **OPTHAL**

PHYSICAL EXAMINATION

PHYSICAL EXAMINATION REPORTED

SUMI M LAB TECHNOLOGIST



Page 1 Of 15



DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA





CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO: 4071WB000781 AGE/SEX :28 Years Female

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED PATIENT ID : ASWAF3007944071 F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

CLIENT PATIENT ID: 27828 DELHI,

SOUTH DELHI 110030 ABHA NO 8800465156

DRAWN

RECEIVED: 04/02/2023 09:12:37 REPORTED :05/02/2023 13:22:50

Test Report Status Results Units **Preliminary**

HAEMATOLOGY - CBC					
MEDIWHEEL HEALTH CHECKUP BELOW 40(F)	<u>TMT</u>				
BLOOD COUNTS,EDTA WHOLE BLOOD					
HEMOGLOBIN	12.0	12.0 - 15.0	g/dL		
RED BLOOD CELL COUNT	4.52	3.8 - 4.8	mil/μL		
WHITE BLOOD CELL COUNT	5.66	4.0 - 10.0	thou/µL		
PLATELET COUNT	270	150 - 410	thou/µL		
RBC AND PLATELET INDICES					
HEMATOCRIT	35.6 Low	36 - 46	%		
MEAN CORPUSCULAR VOL	78.7 Low	83 - 101	fL		
MEAN CORPUSCULAR HGB.	26.5 Low	27.0 - 32.0	pg		
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION	33.7	31.5 - 34.5	g/dL		
RED CELL DISTRIBUTION WIDTH	13.5	11.6 - 14.0	%		
MENTZER INDEX	17.4				
WBC DIFFERENTIAL COUNT					
SEGMENTED NEUTROPHILS	56	40 - 80	%		
LYMPHOCYTES	40	20 - 40	%		
MONOCYTES	02	2 - 10	%		
EOSINOPHILS	02	1 - 6	%		
BASOPHILS	00	< 1 - 2	%		
ABSOLUTE NEUTROPHIL COUNT	3.17	2.0 - 7.0	thou/µL		
ABSOLUTE LYMPHOCYTE COUNT	2.26	1.0 - 3.0	thou/µL		
ABSOLUTE MONOCYTE COUNT	0.11 Low	0.2 - 1.0	thou/µL		
ABSOLUTE EOSINOPHIL COUNT	0.11	0.02 - 0.50	thou/µL		
ABSOLUTE BASOPHIL COUNT	00		thou/µL		
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.4				
ERYTHROCYTE SEDIMENTATION RATE (ESR), BLOOD	WHOLE				
SEDIMENTATION RATE (ESR)	08	0 - 20	mm at 1 hr		
SUGAR URINE - POST PRANDIAL					
SUGAR URINE - POST PRANDIAL	NOT DETECTED	NOT DETECTED			

DR.KARTHIKA RAMANATHAN, M.D Pathology (Reg No - TCMC 53950)

CONSULTANT PATHOLOGIST

SUGAR URINE - FASTING

LAB TECHNOLOGIST

LAVANYA





Page 2 Of 15

DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA





REF. DOCTOR: SELF PATIENT NAME: ASWATHY BABU V

CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO : 4071WB000781 AGE/SEX :28 Years Female MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

DRAWN

RECEIVED: 04/02/2023 09:12:37

REPORTED :05/02/2023 13:22:50

Test Report Status Units **Preliminary** Results

ABHA NO

SUGAR URINE - FASTING

NOT DETECTED

NOT DETECTED

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE:

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. SUGAR URINE - POST PRANDIAL-METHOD: DIPSTICK/BENEDICT'S TEST

SUGAR URINE - FASTING-METHOD: DIPSTICK/BENEDICT'S TEST

DR.KARTHIKA RAMANATHAN, M.D Pathology (Reg No - TCMC 53950) **CONSULTANT PATHOLOGIST**

LAVANYA LAB TECHNOLOGIST





Page 3 Of 15

View Report



DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA





CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO: 4071WB000781 AGE/SEX :28 Years Female

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID

: ASWAF3007944071

CLIENT PATIENT ID: 27828 ABHA NO

DRAWN

RECEIVED: 04/02/2023 09:12:37 REPORTED :05/02/2023 13:22:50

Test Report Status Results Units **Preliminary**

IMMUNOHAEMATOLOGY

MEDIWHEEL HEALTH CHECKUP BELOW 40(F)TMT ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE O **ABO GROUP** RH TYPE **POSITIVE**

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

DR.KARTHIKA RAMANATHAN, M.D **Pathology** (Reg No - TCMC 53950) **CONSULTANT PATHOLOGIST**

LAVANYA LAB TECHNOLOGIST





Page 4 Of 15



DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA





CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO: 4071WB000781 AGE/SEX :28 Years Female MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

ABHA NO

DRAWN

RECEIVED: 04/02/2023 09:12:37 REPORTED :05/02/2023 13:22:50

Test Report Status Results Units **Preliminary**

BIO CHEMISTRY

MEDIWHEEL HEALTH CHECKUP BELOW 40(F)TMT

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 10 Adult(<60 yrs): 6 to 20 mg/dL

BUN/CREAT RATIO

18.5 BUN/CREAT RATIO

CREATININE, SERUM

CREATININE 0.54 18 - 60 yrs : 0.6 - 1.1 mg/dL

GLUCOSE, POST-PRANDIAL, PLASMA

GLUCOSE, POST-PRANDIAL, PLASMA 89 Diabetes Mellitus : > or = 200 mg/dL

> Impaired Glucose tolerance/ Prediabetes: 140 - 199. Hypoglycemia: < 55.

GLUCOSE FASTING, FLUORIDE PLASMA

Diabetes Mellitus: > or = 126 mg/dL GLUCOSE, FASTING, PLASMA 89

> Impaired fasting Glucose/ Prediabetes: 101 - 125. Hypoglycemia : < 55.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

GLYCOSYLATED HEMOGLOBIN (HBA1C) 4.7 Normal : 4.0 -

5.6%.

Non-diabetic level : < 5.7%. Diabetic : >6.5%

Glycemic control goal

More stringent goal : < 6.5 %. General goal : < 7%. Less stringent goal : < 8%.

Glycemic targets in CKD :-If eGFR > 60 : < 7%. If eGFR < 60 : 7 - 8.5%.

MEAN PLASMA GLUCOSE 88.2 < 116.0 mg/dL

LIVER FUNCTION TEST WITH GGT

BILIRUBIN, TOTAL 0.56 General Range: < 1.1 mg/dL

DEVAYANI SATHEESAN

DR.AKHILA SEKHAR, M.D Pathology (Reg No - TCMC 55174) **CONSULTANT PATHOLOGIST**

%





Page 5 Of 15



LAB TECHNOLOGIST

DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA

Tel: 93334 93334

Email: customercare.ddrc@srl.in





CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO: 4071WB000781 AGE/SEX :28 Years Female MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

ABHA NO

DRAWN

RECEIVED: 04/02/2023 09:12:37

REPORTED :05/02/2023 13:22:50

		1	
Test Report Status <u>Preliminary</u>	Results		Units
BILIRUBIN, DIRECT	0.19	General Range : < 0.3	mg/dL
BILIRUBIN, INDIRECT	0.37	0.00 - 0.60	mg/dL
TOTAL PROTEIN	7.2	Ambulatory: 6.4 - 8.3 Recumbant: 6 - 7.8	g/dL
ALBUMIN	4.9	20-60yrs: 3.5 - 5.2	g/dL
GLOBULIN	2.3	General Range : 2 - 3.5 Premature Neonates : 0.29 - 1.04	g/dL
ALBUMIN/GLOBULIN RATIO	2.1 High	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	16	Adults: < 33	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	17	Adults: < 34	U/L
ALKALINE PHOSPHATASE	71	Adult (<60yrs) : 35 - 105	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	16	Adult (female) : < 40	U/L
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.2	Ambulatory: 6.4 - 8.3 Recumbant: 6 - 7.8	g/dL
URIC ACID, SERUM			
URIC ACID	3.4	Adults: 2.4-5.7	mg/dL

Interpretation(s)

DELOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract

Videous problems, such as kidney departs on failure, infection, or reduced blood flow.

- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- · Mvasthenia Gravis
- Muscular dystrophy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in

Diabetes mellitus, Cushing' s syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in



DEVAYANI SATHEESAN LAB TECHNOLOGIST

DR.AKHILA SEKHAR, M.D Pathology (Reg No - TCMC 55174) **CONSULTANT PATHOLOGIST**





Page 6 Of 15

PERFORMED AT:

DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA





REF. DOCTOR: SELF PATIENT NAME: ASWATHY BABU V

CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO : 4071WB000781 AGE/SEX :28 Years Female MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

ABHA NO

DRAWN

RECEIVED: 04/02/2023 09:12:37

REPORTED :05/02/2023 13:22:50

Test Report Status Units **Preliminary** Results

Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1.Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.
 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to:I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

recommended for detecting a hemoglobinopathy
TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum..Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom''''''' disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

DEVAYANI SATHEESAN LAB TECHNOLOGIST

DR.AKHILA SEKHAR, M.D Pathology (Reg No - TCMC 55174) **CONSULTANT PATHOLOGIST**





Page 7 Of 15

View Report



DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA





CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO: 4071WB000781 AGE/SEX :28 Years Female MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

ABHA NO

DRAWN

RECEIVED: 04/02/2023 09:12:37 REPORTED :05/02/2023 13:22:50

Test Report Status Results Units **Preliminary**

BIOCHEMISTRY - LIPID

MEDIWHEEL HEALTH CHECKUP BELOW 40(F)TMT

LIPID PROFILE, SERUM	_	
CHOLESTEROL	123	Desirable : < 200 mg/dL Borderline : 200-239 High : >or= 240
TRIGLYCERIDES	77	Normal : < 150 mg/dL High : 150-199 Hypertriglyceridemia : 200-499 Very High : > 499
HDL CHOLESTEROL	45	General range: 40-60 mg/dL
DIRECT LDL CHOLESTEROL	85	Optimum : < 100 mg/dL Above Optimum : 100-139 Borderline High : 130-159 High : 160-189 Very High : >or= 190
NON HDL CHOLESTEROL	78	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220
VERY LOW DENSITY LIPOPROTEIN	15.4	Desirable value : mg/dL 10 - 35
CHOL/HDL RATIO	2.7 Low	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk
LDL/HDL RATIO	1.9	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

Interpretation(s)

- 1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.
- 2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated

DEVAYANI SATHEESAN LAB TECHNOLOGIST

DR.AKHILA SEKHAR, M.D Pathology (Reg No - TCMC 55174) **CONSULTANT PATHOLOGIST**





Page 8 Of 15

PERFORMED AT:

DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in





REF. DOCTOR: SELF PATIENT NAME: ASWATHY BABU V

CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO: 4071WB000781 AGE/SEX :28 Years Female MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

ABHA NO

DRAWN

RECEIVED: 04/02/2023 09:12:37

REPORTED :05/02/2023 13:22:50

Test Report Status Results Units **Preliminary**

apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category					
Extreme risk group	A.CAD with > 1 feature of high risk group				
		group or recurrent ACS (within 1 year) despite LDL-C			
	< or = 50 mg/dl or polyvascular disease	< or = 50 mg/dl or polyvascular disease			
Very High Risk		major risk factors or evidence of end organ damage 3.			
	Familial Homozygous Hypercholesterolemi	a			
High Risk	1. Three major ASCVD risk factors. 2. Dia	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end			
	organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6.				
	Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid				
	plaque				
Moderate Risk	2 major ASCVD risk factors				
Low Risk	0-1 major ASCVD risk factors				
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	nctors			
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use					
2. Family history of premature ASCVD 4. High blood pressure					
5. Low HDL					

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy		
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)	
Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80	
Category A	$\langle OR = 30 \rangle$	< OR = 60)			
Extreme Risk Group	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60	
Category B					
Very High Risk	<50	<80	>OR= 50	>OR= 80	
High Risk	<70	<100	>OR= 70	>OR= 100	

DEVAYANI SATHEESAN LAB TECHNOLOGIST

DR.AKHILA SEKHAR, M.D Pathology (Reg No - TCMC 55174) **CONSULTANT PATHOLOGIST**





Page 9 Of 15

View Report



8800465156



PATIENT NAME: ASWATHY BABU V REF. DOCTOR: SELF

CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO: 4071WB000781 AGE/SEX :28 Years Female

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED PATIENT ID : ASWAF3007944071 F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DRAWN

CLIENT PATIENT ID: 27828 RECEIVED: 04/02/2023 09:12:37 DELHI, REPORTED :05/02/2023 13:22:50 SOUTH DELHI 110030 ABHA NO

Test Report Status Preliminary Results Units

Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

DEVAYANI SATHEESAN LAB TECHNOLOGIST


DR.AKHILA SEKHAR, M.D Pathology (Reg No - TCMC 55174) **CONSULTANT PATHOLOGIST**





Page 10 Of 15

View Report



DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA





CODE/NAME & ADDRESS : CA00010147 - ACCESSION NO : **4071WB000781** AGE/SEX : 28 Years Female

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

| |PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

ABHA NO :

DRAWN

RECEIVED : 04/02/2023 09:12:37

REPORTED :05/02/2023 13:22:50

Test Report Status <u>Preliminary</u> Results Units

SPECIALISED CHEMISTRY - HORMONE

MEDIWHEEL HEALTH CHECKUP BELOW 40(F)TMT

THYROID PANEL, SERUM

T3 117.50 Non-Pregnant: 80-200 ng/dL

Pregnant Trimester-wise

1st: 81-190 2nd: 100-260 3rd: 100-260

T4 7.85 Adults: 4.5-12.1
TSH 3RD GENERATION 1.240 Non-Pregnant: 0.4-4.2

Non-Pregnant : 0.4-4.2 µIU/mL

µg/dl

Pregnant Trimester-wise:

1st : 0.1 - 2.5 2nd : 0.2 - 3 3rd : 0.3 - 3

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism

VAREENIYA P LAB TECHNOLOGIST DR. AMJAD A, M.D Pathology (Reg No - TCMC 38949) CONSULTANT PATHOLOGIST



Page 11 Of 15

View Details

View Report



DDRC SRL DIAGNOSTICS
Phoenix Tower, Near Central Park Hotel,
Prathibha Junction, Kadappakada,
KOLLAM, 691008

KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in





CODE/NAME & ADDRESS : CA00010147 - ACCESSION NO : **4071WB000781** AGE/SEX : 28 Years Female

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

ABHA NO :

DRAWN

RECEIVED : 04/02/2023 09:12:37

REPORTED :05/02/2023 13:22:50

Test Report Status <u>Preliminary</u> Results Units

4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

VAREENIYA P LAB TECHNOLOGIST DR. AMJAD A, M.D Pathology (Reg No - TCMC 38949) CONSULTANT PATHOLOGIST



Page 12 Of 15

View Details

Patient Ref. No. 666000003272367

View Report



KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in



CODE/NAME & ADDRESS : CA00010147 - ACCESSION NO : **4071WB000781** AGE/SEX : 28 Years Female

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

ABHA NO :

DRAWN

RECEIVED : 04/02/2023 09:12:37

REPORTED :05/02/2023 13:22:50

Test Report Status Preliminary Results Units

CLINICAL PATH - URINALYSIS

MEDIWHEEL HEALTH CHECKUP BELOW 40(F)TMT

PHYSICAL EXAMINATION, URINE

COLOR	PALE YELLOW
APPEARANCE	SLIGHTLY HAZY

CHEMICAL EXAMINATION, URINE

PH	6.0	4.8 - 7.4
SPECIFIC GRAVITY	1.025	1.015 - 1.030
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NORMAL	NORMAL
NITRITE	NOT DETECTED	NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
WBC	2-3	0-5	/HPF
EPITHELIAL CELLS	3-5	0-5	/HPF
0.4.0770	A 171		

CASTS NIL CRYSTALS NIL

BACTERIA NOT DETECTED NOT DETECTED

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis

LAVANYA LAB TECHNOLOGIST DR.KARTHIKA RAMANATHAN, M.D Pathology (Reg No - TCMC 53950) CONSULTANT PATHOLOGIST



Page 13 Of 15







DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA





CODE/NAME & ADDRESS : CA00010147 -ACCESSION NO: 4071WB000781 AGE/SEX :28 Years Female

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

ABHA NO

DRAWN

RECEIVED: 04/02/2023 09:12:37

REPORTED :05/02/2023 13:22:50

Units **Test Report Status Preliminary** Results


Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

LAVANYA LAB TECHNOLOGIST

DR.KARTHIKA RAMANATHAN, M.D Pathology (Reg No - TCMC 53950) **CONSULTANT PATHOLOGIST**



Page 14 Of 15



KOLLAM, 691008 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in



Patient Ref. No. 666000003272367



 CODE/NAME & ADDRESS : CA00010147 ACCESSION NO : 4071WB000781
 AGE/SEX : 28 Years
 Female

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI,

DELHI,

SOUTH DELHI 110030

8800465156

PATIENT ID : ASWAF3007944071

CLIENT PATIENT ID: 27828

ABHA NO :

DRAWN :

RECEIVED : 04/02/2023 09:12:37

REPORTED :05/02/2023 13:22:50

Test Report Status Preliminary Results Units

CLINICAL PATH - STOOL ANALYSIS

MEDIWHEEL HEALTH CHECKUP BELOW 40(F)TMTRESULT PENDINGPHYSICAL EXAMINATION,STOOLRESULT PENDINGCHEMICAL EXAMINATION,STOOLRESULT PENDINGMICROSCOPIC EXAMINATION,STOOLRESULT PENDING

Page 15 Of 15





View Details

View Repor



DDRC SRL DIAGNOSTICS Phoenix Tower, Near Central Park Hotel, Prathibha Junction, Kadappakada, KOLLAM, 691008 KERALA, INDIA



2/4/23, 11:10 AM

CaseSummary

© Report Date € 2023-02-04 Medical Record No.: 03-127325 Was and Company

Patient Name: MS. ASWATHY BABU Start Time: 2023-02-04 10:51

Start Time:

PG: Dr

Consultant: Dr.ANJU SURESH

Age: 28 Years Sex: Female

Start Time: 2023-02-04 10:59

Purpose of Visit:

Regular checkup--

Main Complaints

Z

Eye Symptom Description Duration Ca

Remarks

Onset

Progression

Associated Symptoms

REMARKS: H/O Glass using since at 12 yrs and present pgp at 6 months (Not Brought)

Past Ocular History

Eye Disease Duration

<u>Z</u>

Unit Past Surgery

Surgery Date

Previous Medication

Past Investigation

Other Trtmt

Past Medical History

Description Duration

Unit Past Surgery Z

Surgery Date

Previous Medication

Past Investigation

Prev Hospitalization

Family History

Relation

Age

Duration

Unit

Treatment

Z O Status

Allergy History

Not aware of Allergy Type

Allergen

Not Aware Of

AllergyReaction

History entered by Optometrist was reviewed and Authorized by Dr.ANJU SURESH

Visual Acuity/Refraction

VISUAL ACUITY

Pratibha Junation,Kadappakkada,Kollam-691008 Chaithanya Eye Hospitol & Research Institute Chaitheriva Fva Hacking of Colloplasty

Without Glass

CaseSummary

With Glass

With PH

					.3					
SO	OD	Eye			SO.	OD :			SO	00
		DSph							6/18 (0.50)	6/18 (
1	i	3			2	2.00		TYP	(0.50)	0.50)
					00	8		TYPE OF CHART		
-2.0	-2.00	DC)			*			CHAR		
0	0		Di		ý,					
			Distance Vision		90	70		į.		
90	70	Axis	Visio						i. I-	
					6/6 (0.00)	6/6 (C			1	1
6/6	6/1	В			.00)	.00)				
6/6 (0.00	3 (0.00	BCVA							1	1
٣	٣									
									1	!
0	9	щ		9					:	
Ś	Ō	ye		ASS	OS	8	AC		1.4	
		-		GLASS PRESCRIPTION			ACCEPTANC			
		DSph		CRIP	1	ł	ANCE		ł.	Ė
1	ļ			NOIL	- N6	- N6	111	; ·		
			Add					NEAR VISION CHART		
8 6	2 6	BCVA	σ.					S VISIO		
					ן סי	1		ON CE		
					Prefers new glass	Prefers new glass		ART	1	1
		cm			new gl	new gl				
1	1				ass	ass				
Prefers new glass	Prefers new glass	Preference						:		
s new	s new	ence							1.	
glass	glass									
			Þ					N Char		
			Acceptance					ĭ	- 6/6 (0.00)	- 6/6 (0.00)
			ınce						0.00)	0.00)

Lash and Conjunctiva

Conjunctiva	Lids		
Normal	Normal	OD	

Normal Normal S

Lens	Iris	Iris/ Lens		Sclera	AC	Cornea	Cornea/Anterior Chamber
Normal	Normal			Normal	Normal		amber
Normal	Normal			Normal	Normal	Normal	

Normal	Normal	Normal Normal

Fundus Cont	Retinal Vessels	Macula	Disc	Vitroues		Fundus	
	Normal	Normal	Normal	Normal	OB		

Dr. ANJU SUTTCH MS, DO, FAEH Reg. No: 24665 Consultant-Orbit & Oculoplasty Chaithanya Eye Hospital & Research Institute Pratibha Junction,Kadappakkada,Kollam-691008

Normal Normal

Normal Normal Normal Normal

Retina Choroid

Normal Normal

Diagnosis

<u>Diagnosis</u>

EYE

DESCRIPTION

GENERAL EXAMINATION - V70.9a

Follow Up

FOLLOW-UP

Year(s)

Review After 1

Instructions

External File Uploaded - GLASSGLASSPRESCRIPTION REPORT - file

Examined by Consultant: Dr.ANJU SURESH Time: 04-02-2023 11:00:03

Dr. Alis JU SURES, NS, DO, FAEH
Reg 17, 24666
Consultant- Color & Oculoplasty
Chaithanya Eye Hospilar & Recearch Institute
Pratibha Junction, Kadappakkada, Kollam-691008





ഭാരത സർക്കാർ


es as confisce and common assessing

que Identification Authority of India

Government of India

േത പേർക്കൻ നമ്പർ/ Enrolment No.: 2001/11539/05300

താരാതി ബാബു വി Aswathy Babu V D/O: Babu K Kannitta Puthuvel Neendakara P.O Neendakara Neendakara Kollam Kerala - 691582 9995428413



നിങ്ങളുട്ട് ആധാർ നമ്പർ / Your Aadhaar No. :

2142 2369 2470

VID: 9179 9878 5233 3507


ആധാർ, എന്റെ ഐഡന്റിറ്റി



ഭാരത സർക്കാർ Government of India



അശേതി താലു വി Aswathy Babu V നേന തിമത്/DOB: 30/07/1994 സ്ത്ര∕/ FEMALE



VID: 9179 9878 5233 3507

എന്റെ അധാർ, എന്റെ ഐഡന്റിറ്റി







Susmerce Commence

- 😢 ആധാർ ആധാര് തിരിച്ചറിയലിനുള്ള രേഖയാണ്, പൗരത്വത്തിനുള്ളതല്ല.
- 🗱 തിരിച്ചറിയല് ഓണ്ലൈന് വഴി രാധികാരികമാക്കുക.
- 🏽 ഇത് കമ്പ്യൂട്ടര് വഴി തയ്യാറാക്കിയ കത്താണ്.

INFORMATION


- Aadhaar is a proof of identity, not of citizenship.
- * To establish identity, authenticate online.
- This is electronically generated letter.
- 🏿 ആധാൻ രാജ്യത്തുടനിളം അംഗികാരമുള്ളതാകുന്നു.
- 🖺 ഭാവിയിൽ സർക്കാർ സർക്കാരിതര സേവനങ്ങൾ പ്രയോജനപ്പെടുത്തുന്നതിന് ആധാർ സഹായകമാകും.
- Aadhaar is valid throughout the country.
- Aadhaar will be helpful in availing Government and Non-Government services in future.



ോരത്തെ അവിശേഷ തിരിച്ചുറിയൽ അതോറിറ്റി Unique Identification Authority of India

D/O: നാണ്യ കെ, കന്ന്ട്ര പ്യമവൽ, നീണ്ടകര പി.ജ. ൻടെട്ടു, കോല്ലം, കേട്ടെ - 691582

Address: D/O: Babu K, Kannitta Puthuvei, Neendakara P.O, Neendakara, Kollam, Kerala - 691582



2142 2369 2470

VID: 9179 9878 5233 3507

MENTAL PROPERTY.



MEDICAL EXAMINATION REPORT (MER)

If the examinee is suffering from an acute life threatening situation, you may be obliged to disclose the result of the medical examination to the examinee.

		- 1 2 4 7 4 5 1 2			
 Name of the Mark of Ider Age/Date of Photo ID Ch 	ntification : (Mo Birth :	Mrs./Ms. As Wate de/Scar/any other (speci 3117/1994 sport/Election Card/PA)	fý location) Gender): :: femeleF/M	ompany ID)
HYSICAL DETA	AILS:		No. 10.00 (10.00)		
a Height 16) (cms) b. Wei	ight 57 (Kas)	c (Firth of Abdome	en\$.3 (cms)
	52(/Min) e Blo			tolic I	Section of the sectio
d. Pulsoquic	And the state of t	1 st Reading	//::/:::::::::::::::::::::::::::::::::	110	
		- 2 nd Reading	tiredi missi	711	
		2 Reading		of the	
AMILY HISTO					
Relation	Age if Living	Health Status	If dec	ceased, age at th	e time and cause
Father	61	healthy .		· · · · · · · · · · · · · · · · · · ·	
Mother	56	Lee 1 thy			
Brother(s)	· ·				
Sister(s)			<u> </u>		
HABITS & ADDI	ICTIONS: Does the exam	inee consume any of the	following	?	
					• •
Tobac	co in any form	Sedative	• 1	- 1 A 13 848 X	Alcohol
Tobac		Sedative	*	1000年,前後養養之前 8月1日日本日本人18日	Alcohol
<u> </u>		Sedative	• 1		Alcohol
PERSONAL HIS a. Are you prese	TORY Intly in good health and ental or Physical impairment	tirely free c. Du t or deformity. exa		t 5 years have yo	ou been medically e or treatment or
PERSONAL HIS a. Are you prese from any men If No, please a	TORY Intly in good health and ental or Physical impairment	tirely free c. Du t or deformity. exa Y/N adr	mined, reconitted to an	t 5 years have yo eived any advice y hospital?	ou been medically
PERSONAL HIS a. Are you prese from any men If No, please a b. Have you und procedure?	TORY Intly in good health and enter that or Physical impairment attach details. Interpone/been advised any second controls.	tirely free c. Du t or deformity. exa Y/N adr surgical d. Ha	mined, reconitted to an	t 5 years have yo eived any advice y hospital?	ou been medically e or treatment or Y/N
PERSONAL HIS a. Are you prese from any men If No, please a b. Have you und procedure? Have you ever su	TORY Intly in good health and enter that or Physical impairment attach details. Interpone/been advised any series of the following the follo	tirely free c. Du t or deformity. exa Y/N adr surgical d. Ha Y/N Illowing? disorders of • An	mined, reconitted to an ve you lost	t 5 years have yeeived any advice y hospital? or gained weigh	ou been medically e or treatment or Y/N nt in past 12 months? Y/N nal System? Y/N
PERSONAL HIS a. Are you prese from any men If No, please a b. Have you und procedure? Have you ever su Psychological the Nervous S	TORY Intly in good health and enter that or Physical impairment attach details. Interpone/been advised any series of the following the follo	tirely free c. Du t or deformity. exa	mined, reconitted to an ve you lost	t 5 years have ye eived any advice y hospital? or gained weigh of Gastrointestin	ou been medically e or treatment or Y/N nt in past 12 months? Y/N nal System? Y/N
PERSONAL HIS a. Are you prese from any men If No, please a b. Have you und procedure? Have you ever su Psychological the Nervous S Any disorders	TORY ntly in good health and ental or Physical impairment attach details. ergone/been advised any s ffered from any of the following the fo	tirely free c. Du t or deformity. Y/N adr surgical Y/N d. Ha **Ilowing?** disorders of Y/N • Un and Y/N • Ha	mined, reconitted to an ve you lost y disorder of explained relatively you been	t 5 years have yeeived any advice y hospital? or gained weight	ou been medically e or treatment or Y/N nt in past 12 months? Y/N nal System? Y/N istent fever, Y/N
a. Are you prese from any men If No, please a b. Have you und procedure? Have you ever sure. Psychological the Nervous S. Any disorders.	TORY Intly in good health and enter that or Physical impairment attach details. Interpore the following the foll	tirely free c. Du t or deformity. Y/N adr adr urgical d. Ha Y/N Illowing? disorders of Y/N • Un and Y/N • Ha mour? Y/N	mined, reconitted to an ve you lost y disorder of explained relative you been fore? If yes	t 5 years have yeeived any advice y hospital? or gained weight of Gastrointesting ecurrent or persons tested for HIV attach reports	ou been medically e or treatment or Y/N at in past 12 months? Y/N and System? Y/N istent fever,

DDRC SRL Diagnostics Private Limited

Corp. Office: DDRC SRL Tower, G- 131, Panampilly Nagar, Ernakulam - 682 036 Ph No. 0484-2318223, 2318222, e-mail: info@ddrcsrl.com, web: www.ddrcsrl.com

any disorders of Urinary System?	YAY	 Any disorder Mouth & Sk 		, Ears Nose, Th	roat or
OR FEMALE CANDIDATES ONLY		WOUTH & OK.			
a. Is there any history of diseases of breast/genital		d. Do you have	any history	of miscarriage/	E 18698
organs?	Y/N	' abortion or N	ИТР		Y/N
b. Is there any history of abnormal PAP Smear/Mammogram/USG of Pelvis or any other tests? (If yes attach reports)	Y/M	e. For Parous V during pregn hypertension	ancy such a	e there any com s gestational dia	plication lbetes, Y/N
c. Do you suspect any disease of Uterus, Cervix or	Tiesda i ili	The second secon	L. J	If yes, how man	and the contract of the contra
Ovaries?	YAV	serrapis o per	* * * * * * * * * * * * * * * * * * *		Y/N.
CONFIDENTAIL COMMENTS FROM MEDICA	AL EXA	MINER			
➤ Was the examinee co-operative?					X/N
> Is there anything about the examine's health, life his/her job?	style tha	t might affect hi	m/her in the	near future wit	h regard to
> Are there any points on which you suggest further	er inforn	nation be obtaine	d?		Y/N
> Based on your clinical impression, please provide	le your si	uggestions and re	ecommenda	tions below;	•
Hanking guilt wit Hanke territory (
				A.	
	•••••	*************************	••••••••••••••••••••••••••••••••••••••	***********	*******
> Do you think he/she is MEDICALLY FIT or UN	JEIT for	annlovment l	,		* 1
> 20 you talk holono is with the first 111 of or	VIII IOI	emproyment.	(e)		
			r Valen	AMERIKATAN	
MEDICAL EXAMINER'S DECLARATION				erê yar vî gay	
hereby confirm that I have examined the above indi	vidual af	ter verification of	of his/her ide	entity and the fi	ndings stated
bove are true and correct to the best of my knowled	ge.	· ·		Not so for contact descriptions	*
tomo P. Children and the Prince of The Live Const.	\ \ \ \	no	ANIALIA	AIR V. MBBS	MD
Name & Signature of the Medical Examiner :	7 4 4 6 C	9X	Red	No. 46952	
There is the second second second second		C	ONSULTANT	MICROBIOLOG	151
eal of Medical Examiner :	•	•			
		ing and the second seco	is Otogoti ya	a risionalistatika	12 (소리 15) 정생물 중국원원
The World of Contambination Man Solid	•	Burn Brogger		i vi erbanek() b	*
Name & Seal of DDRC SRL Branch :	DDR	ESALP	V7 490	kadappa l	ckada
(\$ 11 人名 11 人名 11 · 12 · 14 · 14 · 14 · 14 · 14 · 14 ·	154	and the second s	Market Commence of the Commenc	supulusti) -	erina de la composición del composición de la co
Date & Time	4121	22 //55			in the second of the second
्राप्त । विभिन्ने कार्या विभिन्न कार्या का सम्बद्धिक केर्युंग पुरित्र कार्या कार्या । स्थापन			Contract of		at a war en
			PH 94977	320 /	Page 2
DDRC SRL Di	sanac	atine Brive	talimi	fad	garty. Topicon
Corp. Office: DDRC SRL Towe				CONTRACTOR	
Ph No. 0484-2318223, 2318222,	e-mail: in	fo@ddrcsrl.com, v	veb: www.ddr	csrl.com	-

Regd. Office: 4th Floor, Prime Square, Plot No.1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (West), Mumbai – 400062.



NAME: ASWATHY BABU V AGE/ SEX :28/F 04.02.2023

ELECTRO CARDIOGRAM REPORT

ELECTRO CARDIOGRAM

: NSR — .../minute. No evidence of ischaemia or chamber hypertrophy

Impression

: ECG within normal limits.

DR. ANJALI NAIR. V. MBBS, MD Reg. No: 46952 CONSULTANT MICROBIOLOGIST

DR ANJALI NAIR V

MBBS,MD

CONSULTANT MICROBIOLOGIST DDRC SRL DIAGNOSTICS



RADIOLOGY DIVISION

Name: Mrs. Aswathy Babu. V

Age: 28 yrs

Sex: F

Ref. Ref. from. Mediwheel Arcofemi

Date: 04.02.2023

USG OF ABDOMEN (TAS & TVS)

<u>LIVER:</u> Is normal in size (15.0 cms) and echotexture. No focal lesions are seen. No dilatation of intra-hepatic biliary radicles present. Portal vein is normal. Common bile duct is normal.

GALL BLADDER: Is distended. Normal in wall thickness. No calculus or mass.

PANCREAS: Visualized head & body appear normal. Rest obscured by bowel gas.

SPLEEN: Is normal in size (10.7 cms) and echotexture.

<u>RIGHT KIDNEY:</u> Measures 9.8 x 3.8 cms. Normal in size and echotexture. Cortico medullary differentiation is well maintained. No calculus, hydronephrosis or mass.

<u>LEFT KIDNEY:</u> Measures 9.6 x 3.7 cms. Normal in size and echotexture. Cortico medullary differentiation is well maintained. No calculus, hydronephrosis or mass.

<u>URINARY BLADDER:</u> Is minimally distended. Normal wall thickness. No obvious calculus or mass noted.

<u>UTERUS</u>: Measures $7.8 \times 4.4 \times 5.8$ cms. Normal in size. *Small hypoechoic lesions noted - Possibly fibroids*; F(1) - 11.2×5.5 mm in the anterior myometrium, 7.5×8 mm in the fundus. Endometrium measures 6.6 mm.

Right ovary measures - $27 \times 20 \text{ mm}$ Left ovary measures - $29 \times 18 \text{ mm}$ Both ovaries are normal in size and echoes.

No adnexal mass lesion seen. No free fluid in POD.

Both iliac fossae appear normal and there is no obvious evidence of bowel mass or bowel wall thickening present.

IMPRESSION:

Small uterine fibroids.

- Suggested follow up & clinical correlation
- Images overleaf.

Dr. AISALUTH THULASEEDHARAN MBBS, DMRD

(Note: Diagnosis should not be made solely on one investigation. Advised further / repeat investigation and clinical correlation in suspected cases and in case of unexpected results, ultrasound is not 100% accurate and this report is not valid for medico legal purpose)

DDRC SRL Diagnostics Limited

Aster Square, Medical College P.O., Trivandrum - 695 011. Ph: 0471 - 2551125. e-mail: info.ddrc@srl.in, web: www.ddrcsrl.com Corp. Office: DDRC SRL Tower, G-131, Panampilly Nagar, Ernakulam, Kerala - 682 036. Web: www.ddrcsrl.com

Gynecology Report

Patient ID: 04_02_2023_12_35_50

Patient Name : ASWATHY Study Date : 04/02/2023

Referring MD: Performing MD: Sonographer: Indication:

Exam Type: GYN

Height : Gravida :

Weight:

Para:


AB:

Ectopic:

Age:


Sex:F

LMP:









Signature ____



Awatty Babu. V W/o Bichu S Ray EcNo: 116715 Bank of Baroda Kananagapuly

Deen Sir, J didn!! wont to do Stod examination

your faillfully Acoustry Babu V



NAME	AGE/ SEX	DATE
ASWATHY BABU V	28/F	04.02.2023

CHEST X-RAY WITH REPORT

CHEST X-RAY: NORMAL

Impression : Within normal limits

DR. ANJALI NAIR. V. MBBS, MD Reg. No: 46952 CONSULTANT MICROSIOLOGIST

DR ANJALI NAIR V

MBBS,MD

CONSULTANT MICROBIOLOGIST

DDRC SRL DIAGNOSTICS PVT LTD

DUNO SEE DIRORGOSTIOS (T) LTD. TRIVARDRUS, KOTTEXAS, COCTIS, CRICCI,

DDRC Hospital

Protocol: Bruce ASWATHY BABU V (28 F) Chart Speed: 25 mm/sec DUNO MAR DEAGRADATION (P) LTD. TRIVARDATIN, MOTTAVAN, OCCITA, OALIOTE, ST Level 0.0 aVR aVF a¥ Eilter 35 Hz Stage: Standing ID: 2127 Mains Fift ON Amp. 10 mm Speed: 0 mph Date: 04-Feb-23 Exec Time: 0 m 0 s Stage Time: 0 m 16 s HR: 68 bpm Grade: 0 % /so ≠ R - 60 ms J = R + 60 ms (THR: 172 bpm) Post J = J + 60 msX ST Level వ S S 5 5 B.P: 100 / 60 0.0 2 0.0

ASWATHY BABU V (28 F) ID: 2127 Date: 04-Feb-23

Protocol: Bruce


Stage: Hyperventilation Speed: 0 mph


Grade: 0 %


Exec Time: 0 m 0 s Stage Time: 0 m 9 s HR: 61 bpm


(THR: 172 bpm)


B.P: 100 / 60











Date: 04-Feb-23

Exec Time: 10 m 8 s Stage Time: 1 m 0 s HR: 121 bpm

ID: 2127

ASWATHY BABU V (28 F)

Schiller Spandan V 4.7 Chart Speed: 25 mm/sec Protocol: Bruce ST Level aVR ٦VE Filter: 35 Hz Stage: Recovery(1) Mains Filt ON Amp: 10 mm Speed: 0 mph lso = R - 60 msGrade: 0 % J=R+60ms (THR: 172 bpm) Post J = J + 60 msST Level (mm) S S X ś 5 5 B.P: 120 / 60 4

ASWATHY BABU V (28 F) ID: 2127 Date: 04-Feb-23 Exec Time: 10 m 8 s Stage Time: 1 m 0 s HR: 75 bpm (THR: 172 bpm) B.P: 120 / 60


Protocol: Bruce Chart Speed: 25 mm/sec Schiller Spandan V.4.7 ST Level ტ.2 2 ST Slope 0.4 aVL aVR aVF Filter: 35 Hz Stage: Recovery(2) Mains Filt: ON Amp: 10 mm Speed: 0 mph Grade: 0 % /so - R - 60 ms J = R + 60 msPost 1 = 1 + 60 ms ST Level ŝ S S 5

Chart Speed: 25 mm/sec Protocol: Bruce ST Level 0.2 0.0 ST Slope (mV/s) aVR aVF Filter: 35 Hz Mains Filt ON Amp: 10 mm /so = R - 60 ms J = R + 60 ms Post J = J + 60 msST Level (mm) S 3 ર્ક \$ S 5 **○.0**

DORO WAL DIAGROSTICS OF LID. TRIVANDRUM, KOTTAKAM, COCHIN, CALICUT.

ASWATHY BABU V (28 F) ID: 2127 Date: 04-Feb-23 Exec Time: 10 m 8 s Stage Time: 1 m 0 s HR: 70 bpm

Protocol: Bruce Stage: Recovery(4) Speed: 0 mph Grade: 0 % (THR: 172 bpm) B.P: 100 / 60



DURO SEL DIAGROSTICS (P) LTD. TRIVANDELIN, KOTTEXAN, COCTIN, CALICUT.

DDRC Hospital

Κεςονείχ(6)	Recovery(5)	Гесфуелу(4)	Rесоуегу(3)	Recovery(2)	Recovery(1)	PeakEx				Hyperventilation	Standing	Supine			Stage Name	Test Termination Criteria Protocol Details	Max. BP: 1207 60 mmHg	Total Exec. Time:	Test Details Protocol: Bruce		Clinical History:	Age: 28 y	Name: ASWATHY BABUV ID: 2127	Patient Details
	0		10			-1	8	3.0	ပ	0 9	0.16	0 45		(min : sec)	Stage Time		lmHg	10 m 8 s			ROUTINE CHECK UP	Sex. F	ABUV ID: 2127	Date: 0
10	1.0	10	1.0	1.0	.00	13.5	10.2	7.0	4.6	1.0	1.0	1.0			Mets	SI				X	K UP			Date: 04-Feb-23
	0	O	0	q		4.2	3.4	QI KY	1.7	0	9	0		(mph)	Speed									&
	0	0	0	0	0	16	14	į, ζ	10	0	0	0		(%	Grade		Max. BP	Max. HR:	:AHMIA					
8	78	70	73	75	72	150	124	105	94	61	68	70	(bpm)	Rate	e Heart	THE TEST IS TERMINATED DUE TO LEG PAIN	×		192 bp m			Height:162 cms		Time: 1:59:26 PM
100,/60	100 / 60	100 / 60	100 / 60	120 / 60	120 / 60	120 / 60	100 / 60	100 / 60	1001 60	100 (60	100 / 60	100 / 60		(mm/Hg)	Max. BP	PAIN	Wax: BP x: HR: 18000 mmHg/min	150 (78% of P: MHR) bpm				cms		26 PM
0.42	-0,6 4	-0.8511	-1:0611	-1.06	-3.61 III	-3.61 111	-1.7011	-1.27 H	-1.06 II	-0.21	0.21	-0.42 III	(mm)		Max SI		TO T	R) bpm				.		
0.71-1	0.711	1.06 V4	1,421	2,48 [2.83	2.83	1771	1.06 II	0.71	-0.35 aVR	0.71 II	0,35	(mV/s)	Slope	Max, ST		Min. Be x	Max. Mets: 13.50				Weight:57 Kgs		
																	Min. BP × HR: 3660 mmHg/min	s: 13.50	THR: 172 (90 % of Pr.MHR) bpm					
																	0 տրո լ վ ց/ու							
																	5		B					

DEFECT SEEL CHACKNOSTICS (P) LTD.

TELLANDROM, KOTTAKAM, COCHIN, CALICUT,

NEZZANEZAZ MANOILABLE MYDINAZZ X SOLEMAZ							
a rathernus							

DERC SAL DIAGNOSTICS (P) LTD. TRIVANDRUM, KOTTAYAM, COCHIN, CALICUT,

(Summary Report edited by user)